Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

 Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

Shots:

  • Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & holds the global rights for the product outside of China
  • Innovent gets an exclusive license to research, develop and commercialize orismilast (PDE4 Inhibitor) in China, including participating and recruiting Chinese patients for global studies
  • In P-IIa clinical studies, orismilast demonstrated a superior profile with improved efficacy and tolerability. The therapy has provided POC data orally in psoriasis or AD & is well suited to address the unmet needs of the patient populations

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Innovent

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post